Key facts
- This page summarizes L-5 Healthcare Partners, LLC's Form 4 filing for Alphatec Holdings, Inc. (ATEC).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 May 2023, 16:59.
L-5 Healthcare Partners, LLC - 10 May 2023 Form 4 Insider Report for Alphatec Holdings, Inc. (ATEC)
- Reporting relationship
- Director by deputization, 10%+ Owner
- Issuer ticker
- ATEC
- Reported as of
- 10 May 2023
- Net transaction value
- -$25,296,000
- SEC form
- 4
- Accepted by SEC
- 12 May 2023, 16:59:27 UTC
- Prior SEC filing
- 21 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Segal, Manager L-5 Healthcare Partners, LLC
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
L-5 Healthcare Partners, LLC filed Form 4 for Alphatec Holdings, Inc. (ATEC) on 12 May 2023.
Change
- Previous filing in this sequence was filed on 21 Feb 2023.
- Current net transaction value: -$25,296,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATEC
transaction
Common Stock
Sale
- Transaction value
- $25,296,000
- Shares
- -1,700,000
- Change %
- -13%
- Price
- $14.88
- Shares after
- 11,081,538
- Date
- 10 May 2023
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
This price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.88 to $15.67, inclusive. The reporting undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
Footnote F2
Each of Andy Barnett and Evan Bakst serve on the board of directors of the issuer as a representative of the reporting persons. As a result, each reporting person herein may be deemed a director by deputization for the purposes of Section 16 of the Exchange Act.
Footnote F3
Paul Segal directly (through his position as manager of L-5 Healthcare Partners, LLC ("L-5")) may be deemed to control L-5 and to have shared voting and investment power with respect to the shares beneficially owned by L-5. As such, Mr. Segal may be deemed to have shared beneficial ownership of the shares beneficially owned by L-5. Mr. Segal, however, disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest therein.
Footnote F4
Paul Segal separately is the direct beneficial owner of 171,329 shares of Common Stock of the Issuer.